Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study

Health and Quality of Life Outcomes

Michel Henry-Amar¹  Hanneke C. Kluin-Nelemans²  Marleen van der Kaaij³  Berthe M. P. Aleman⁴  Corinne Haioun⁵  Catherine Thiéblemont⁶  René-Olivier Casasnovas⁷  Hervé Tilly⁸  Aspasia Stamatoullas⁸  Vincent Ribrag⁹  Nicolas Mounier^1,10  Raphaël Busson^1,11 

[1] Centre de Traitement des Données du Cancéropôle Nord-Ouest, Plateforme de Recherche Clinique Ligue Contre le Cancer, Centre François Baclesse;Department of Haematology, University Medical Centre Groningen, University of Groningen;Department of Internal Medicine, Leiden University Medical Centre;Department of Radiotherapy, The Netherlands Cancer Institute;Service d’Hématologie, AP-HP CHU Henri Mondor;Service d’Hématologie, AP-HP CHU Saint-Louis;Service d’Hématologie, CHRU de Dijon Bourgogne, Hôpital Le Bocage;Service d’Hématologie, Centre Henri Becquerel;Service d’Hématologie, Gustave Roussy Cancer Campus;Service d’Onco-hématologie, Université Côte d’Azur, Centre Hospitalier Universitaire de Nice;École Doctorale MIIS, University of Caen-Normandie;

关键词: Hodgkin lymphoma;    Non-Hodgkin lymphomas;    Long-term survivors;    Fatigue;    Cross-sectional study;   

DOI  :  10.1186/s12955-019-1186-x

来源: DOAJ

【 摘 要 】

Abstract Background Long-term lymphoma survivors often complain of persistent fatigue that remains unexplained. While largely reported in Hodgkin lymphoma (HL), long-term fatigue is poorly documented in non-Hodgkin lymphomas (NHL). Data collected in two cohort studies were used to illustrate the fatigue level changes with time in the two populations. Methods Two cross-sectional studies were conducted in 2009–2010 (HL) and in 2015 (NHL) in survivors enrolled in European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and Lymphoma Study Association (LYSA) trials. The same protocol and questionnaires were used in both studies including the Multidimensional Fatigue Inventory (MFI) tool to assess fatigue and a checklist of health disorders. Multivariate linear regression models were used in the two populations separately to assess the influence of time since diagnosis and primary treatment, age, gender, education level, cohabitation status, obesity and health disorders on fatigue level changes. Fatigue level changes were compared to general population data. Results Overall, data of 2023 HL and 1619 NHL survivors with fatigue assessment available (99 and 97% of cases, respectively) were analyzed. Crude levels of fatigue were similar in the two populations. Individuals who reported health disorders (61% of HL and 64% of NHL) displayed higher levels of fatigue than those who did not (P <  0.001). HL survivors showed increasing fatigue level with age while in NHL survivors mean fatigue level remained constant until age 70 and increased beyond. HL survivors showed fatigue changes with age higher than those of the general population with health disorders while NHL survivors were in between those of the general population with and without health disorders. Conclusions Among lymphoma survivors progressive increase of fatigue level with time since treatment completion is a distinctive feature of HL. Our data suggest that changes in fatigue level are unlikely to only depend on treatment complications and health disorders. Investigations should be undertaken to identify which factors including biologic mechanisms could explain why a substantial proportion of survivors develop high level of fatigue.

【 授权许可】

Unknown